Sign inJoin waitlistJoin the waitlist

Manik Amin

Assistant Professor of Medicine · University of Chicago Medical Center

Credentials: · · · · · · ·

History

University of Chicago Medical Center
Present
University of Chicago Medical Center
Present

Hematology and Medical Oncology
Washington University/B-JH/SLCH Consortium
2012–2015
University of Kansas School of Medicine
2010–2012
University of Kansas Hospital and Medical Center
2003–2006
John H. Stroger Jr. Hospital of Cook County
2000–2003
Internal Medicine
Barnes-Jewish Hospital
1997–2000
MAHATMA GANDHI INSTITUTE OF MEDICAL SCIENCES, NAGPUR UNIV, WARDHA, MAHARASHTRA
1993–1997

Research

First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors
Cancer immunology · 2023 · 114 citations
Systemic Therapy for Combined Hepatocellular-Cholangiocarcinoma: A Single-Institution Experience
Journal of the National Comprehensive Cancer Network · 2018 · 65 citations
A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid…
Investigational New Drugs · 2016 · First of 12 authors · 43 citations

BT
Benjamin Tan
14 papers
Andrea Wang-Gillam
10 papers
Nikolaos Trikalinos
9 papers
Craig Lockhart
7 papers
KL
Kian-Huat Lim
7 papers
RS
Rama Suresh
7 papers
HP
Haeseong Park
6 papers
KP
Katrina Pedersen
6 papers
AA
Amit Amin
4 papers · 4 as a resident
PG
Patrick Grierson
4 papers · 2 as a fellow
Elizabeth Brunt
3 papers
Gabriel Brooks
3 papers

Clinical trials

Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers
Principal investigator · Not yet recruiting · Phase 2
University of Chicago
2026–2028
Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer
Principal investigator · Completed · Phase 2
Washington University School of Medicine
2013–2015
Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
Site PI · Recruiting · Phase 2
University of Chicago
2025–2029
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2023–2028